2019
DOI: 10.1016/j.jval.2019.05.014
|View full text |Cite
|
Sign up to set email alerts
|

On the Optimization of Bayesian D-Efficient Discrete Choice Experiment Designs for the Estimation of QALY Tariffs That Are Corrected for Nonlinear Time Preferences

Abstract: Objectives: This article explains how to optimize Bayesian D-efficient discrete choice experiment (DCE) designs for the estimation of quality-adjusted life year (QALY) tariffs that are unconfounded by respondents' time preferences. Methods:The calculation of Bayesian D-errors is explained for DCE designs that allow for the disentanglement of respondents' time and health-state preferences. Time preferences are modelled via an exponential, hyperbolic, or power discount function and the performance of the propose… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
7
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

1
6

Authors

Journals

citations
Cited by 11 publications
(8 citation statements)
references
References 23 publications
1
7
0
Order By: Relevance
“…More specifically, a Bayesian heterogeneous D-efficient DCE design with 10 subdesigns and 15 pairwise choice tasks per subdesign was optimized using the TPC-QALY software package. 22 This implied a simultaneous optimization of the efficiency of the 10 separate designs as well as the efficiency of the overall design. The D-efficiency criterion was calculated with 100 Bayesian draws, assuming an exponential discount function and based on the weighted average of the overall (i.e., combined) D-error (25% weight) and D-errors of the 10 subdesigns (75% weight).…”
Section: Methodsmentioning
confidence: 99%
“…More specifically, a Bayesian heterogeneous D-efficient DCE design with 10 subdesigns and 15 pairwise choice tasks per subdesign was optimized using the TPC-QALY software package. 22 This implied a simultaneous optimization of the efficiency of the 10 separate designs as well as the efficiency of the overall design. The D-efficiency criterion was calculated with 100 Bayesian draws, assuming an exponential discount function and based on the weighted average of the overall (i.e., combined) D-error (25% weight) and D-errors of the 10 subdesigns (75% weight).…”
Section: Methodsmentioning
confidence: 99%
“…Indeed, heterogeneous designs allow for a greater variation in the attribute levels, that is, a higher number of choice sets, without increasing the cognitive burden for the respondents. Following Jonker and Bliemer (2019) and de Bekker‐Grob et al (2020), we generated a heterogeneous design consisting of 4 sub‐designs with 16 choice sets each (one sub‐design per each group defined by the four reference prices). Every sub‐design was divided into two blocks of eight choice tasks to further reduce the cognitive burden on respondents and to mitigate fatigue effects.…”
Section: Methodsmentioning
confidence: 99%
“…9 Second, DCEs are generally considered to be cognitively burdensome to respondents, making them less than ideal for participants who have cognitive impairments. 17,18 In addition, they require relatively large sample sizes, 19 making them inappropriate for administration in, for example, rare disease populations. The combination of expert input and large sample size renders relatively high study costs and long study duration.…”
mentioning
confidence: 99%
“…The combination of expert input and large sample size renders relatively high study costs and long study duration. 18,19 Researchers as well as stakeholders who use preference information (i.e., representatives from the pharmaceutical industry and regulatory and reimbursement bodies) have expressed the need to compare DCEs to other, simpler methods. 22 This will help guide method selection for use in patient preference studies that are budget and or time sensitive, conducted in rare disease areas, and for which Marginal Rate of Substitution (MRS) or predicted uptake are not among the required outcome measures (e.g., prioritization of unmet medical needs or endpoint selection for clinical trials).…”
mentioning
confidence: 99%
See 1 more Smart Citation